A 59 review meta analysis from the University of Sydney finds opioid relief for acute pain is real but narrow, and the side effect tradeoff starts within hours.
For decades, the opioid prescription after a procedure, an injury, or a difficult delivery has been almost automatic. The largest evidence review ever compiled on opioids for acute pain challenges that default. Across 59 systematic reviews covering more than 50 acute pain conditions in children and adults, oral opioids performed no better than placebo for several common situations, and where they did help, the benefit was small and short-lived, typically fading within hours.
The University of Sydney-led review, summarized by ScienceDaily on 9 June 2026 and published in the peer-reviewed journal Drugs, is the broadest synthesis of the acute-pain opioid literature to date. It was led by Associate Professor Christina Abdel Shaheed of the university's School of Public Health, with Dr. Stephanie Mathieson and Associate Professor Joshua Zadro of the Institute for Musculoskeletal Health as co-first authors.
The conditions where opioids showed a modest, time-limited edge are specific: stomach pain, pain after dental or ear procedures, traumatic limb injuries, childbirth, caesarean delivery, and bunionectomy. In each of these, patients who got an opioid reported slightly lower pain scores than those on placebo, but the advantage rarely stretched past the first day or two of treatment.
The list of conditions where opioids matched placebo is longer and more uncomfortable for routine practice. Some limb surgeries, kidney stone pain, post-tonsil removal pain, and pain in newborns on assisted breathing all failed to separate from placebo in the underlying trials. For heart-related pain, post-hysterectomy pain, and topical opioid patches used in dermatology, the evidence was inconsistent, leaving clinicians without a clear signal one way or the other.
The benefit came with a cost. Across acute musculoskeletal pain, traumatic limb injuries, and several post-surgical settings, opioid users reported higher rates of nausea and vomiting than those on placebo, a tradeoff that starts within a single dose. The authors also flagged longer-term risks that begin to accrue quickly: tolerance, dependence, misuse, overdose, hospitalization, and death. Persistent opioid use, they warn, can take hold within days of a first prescription, including from a short course taken for an acute problem.
A few limits are worth naming. Many of the underlying trials inadequately reported side effects, and some tested only a single dose, which makes it hard to translate the findings into the real rhythms of post-surgical or post-injury care. The Sydney team also notes that the underlying journal article should be consulted for precise effect sizes by condition, and that the press-release framing of "often don't work" is shorthand for a more precise result: small, short-lived benefit on average, with a noisy condition-by-condition picture.
What the evidence map does support is a tighter, more deliberate use of opioids for acute pain. For a patient about to have a procedure, the practical question is no longer whether an opioid is the strongest available option, but whether the expected hours of relief justify the side effects and the small but real risk of sliding into longer-term use. For prescribers, the review supplies a meta-level spine for shared decision-making and for defaulting to non-opioid options where the evidence is thin. For health systems weighing prescribing guardrails, 59 systematic reviews is a hard number to argue with, and the next watch item is whether clinical guidelines begin to retire opioid-first defaults for the conditions on the placebo-equivalent list.